Roche Cervical Cancer Diagnostic Test Approved in China

Roche has been granted CFDA approval for its CINtec ® PLUS Cytology test, which detects pre-cancerous cervical disease. In a China study, the CINtec Plus test was more effective than conventional screening tools such as the Pap smear for selecting the patients with the greatest risk of developing cervical cancer. Roche's Diagnostic Division is a major part of its China operation, and the CINtec Plus test joins Roche's other cervical cancer diagnostics -- the cobas® HPV Test for screening, CINtec ® PLUS Cytology and CINtec ® Histology for triage and diagnosis -- in women's health. More details.... Stock Symbol: (SIX: RO, ROG) Share this with colleagues: // //